1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Apr 2025 | |
|---|---|---|
| Revenue | 448.82K | - |
| Gross profit | 448.82K | - |
| Net profit | -42.39K | - |
| EBITDA | 33.86K | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €5.58M |
Number of shares | 312.86M |
52-week high/low | €0.30 - €0.00198 |
| Dividends | No |
Beta | 4.38 |
P/E ratio | -0.09 |
PEG ratio | 0.00 |
P/B ratio | 0.24 |
P/S ratio | 1.46 |
Company profile
Universal Ibogaine Inc. ist ein biowissenschaftliches Unternehmen, das Kliniken zur Suchtbehandlung in Kanada entwickelt, erwirbt und betreibt. Es führt geplante klinische Studien zur Erforschung der Verwendung von Ibogaine zur Suchtbehandlung durch. Der Hauptsitz des Unternehmens befindet sich in Calgary, Kanada.
| Name | UNIVERSAL IBOGAINE INC. Aktie |
| CEO | Nicholas Peter Karos |
| Headquarters | Calgary,
ab Canada |
| Website | |
| IPO | 06/22/2017 |
| Employees | 7 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Tsxv | IBO.V |
Pnk | IBOGF |
Frankfurt | JC4.F |
München | JC4.MU |
Discover assets
Shareholders of UNIVERSAL IBOGAINE INC. Aktie also invest in the following assets
